On Tuesday, Humana Inc. (NYSE:HUM) posted a fourth-quarter adjusted EPS loss of $(2.16), down from $(0.11) a year ago, in line with the consensus and including incremental investments in Stars.
The company reported revenues of $29.19 billion, up 13.5% year-over-year from $25.73 billion, beating the consensus of $28.84 billion, primarily driven by higher per-member Medicare premiums and Medicare Advantage and state-based contracts membership growth, offset by a decline in stand-alone PDP membership, and a decline in membership in the group commercial medical business as a result of the company’s decision to exit the business.
Also Read: RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Humana ended the fourth quarter with 16.35 million in total medical membership, compared to 16.86 million a year ago. Individual Medicare Advantage membership reached 5.66 million, up from 5.67 million a year ago.
Humana says the insurance segment adjusted benefit ratio of 91.9%, which includes a 20-basis point increase related to incremental Star Ratings investments, was consistent with expectations.
Guidance: Humana expects 2025 GAAP sales of $126 billion-$128 billion versus the consensus of $119.41 billion.
Sales guidance includes Insurance segment sales of $121 billion—$123 billion and CenterWell segment sales of $20.5 billion—$21.5 billion.
The insurer expects individual Medicare Advantage annual membership decline of approximately 550,000, or approximately 10%, from 2024, inclusive of the company’s decision to exit certain unprofitable plans and counties, with group Medicare Advantage to remain relatively flat and Medicare stand-alone PDP growth of approximately 200,000.
Humana reaffirms the 2025 adjusted EPS outlook of $16.25 versus the consensus of $16.71.
For 2025, Humana expects its insurance segment’s benefit ratio guidance of approximately 90.1-90.5%.
In prepared remarks, Humana said, “Our 2025 MA pricing strategy was focused on resetting pricing and membership to more accurately reflect the funding and medical cost trend environment, improving underlying margins.”
Price Action: HUM stock is up 3.07% at $274.99 during the premarket session on last check on Tuesday.
Read Next:
Photo: T. Schneider via Shutterstock
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。